. TRADITIONAL CHINESE MEDICINE ACUPOINT PASTING FOR PREVENTING AND TREATING GASTROINTESTINAL REACTIONS IN TYPE II DIABETES MELLITUS PATIENTS UNDERGOING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY: A CLINICAL STUDY
Serum level of glycated Hb (HbA1c), fasting INS (FINS), INS β secretion (HOMA-β), erythrocyte sedimentation rate in Type II Diabetes
Abstract
Introduction: Serum level of glycated Hb (HbA1c), fasting INS (FINS), INS β secretion (HOMA-β), in Type II Diabetes Mellitus Patients Undergoing Glucagon-Like Peptide-1 Receptor Agonist Therapy were evaluated. Materials and Methods: this study randomly assigned 315 patients starting GLP-1RA therapy into a control group (CG, standard treatment + routine care), a placebo group (PG, placebo + routine care), and a traditional Chinese medicine (TCM) group (TG, TCM plaster therapy + routine care). The glycemic control, pancreatic function, hematological parameters, renal function, and adverse reactions (ARs) were compared among the groups. Results:the TG group exhibited no significant differences in fasting blood glucose (FBG), postprandial blood glucose at two hours, glycated hemoglobin (Hb), fasting insulin (FINS) levels, β-cell insulin secretion, and insulin resistance (IR) when compared to the CG and the PG (P>0.05). Additionally, there were no significant changes in Hb, white blood cell (WBC) count, and erythrocyte sedimentation rate (ESR) in the TG relative to the CG and PG (P>0.05). Renal function indicators revealed that the levels of blood urea nitrogen (BUN) and serum creatinine (Cr) in the TG did not differ significantly from those in the CG and the PG (P>0.05). The incidence of ARs in TG (8.57%) was markedly lower than in PG (17.14%) and CG (18.1%) (P<0.05). Conclusion:the application of TCM Liangfu Pills via acupoint plaster did not demonstrate significant therapeutic effects on glycemic control, pancreatic function, or routine blood parameters. However, it was effective in significantly reducing the risk of gastrointestinal adverse reactions associated with GLP-1RA therapy.
References
1. Liu H, Tang T. MAPK signaling pathway-based glioma subtypes, machine-learning risk model, and key hub proteins identification. Scientific Reports, 2023;13(1):19055(1-16).
2. Mallik N, Singh N, Jamwal M, Chhabra S, Hira JK, Malhotra P, Das R, Sharma P. A novel ATRX splice variant causing acquired HbH disease in myelodysplastic syndrome with excess blasts-1. Cancer Genetics, 2022;260-261:53-56.
3. Liu L, Zhang J, Cheng Y, Zhu M, Xiao Z, Ruan G, Wei Y. Gut microbiota: A new target for T2DM prevention and treatment. Frontiers in endocrinology, 2022;13:958218(1-9).
4. Zhou Z, Sun B, Yu D, Zhu C. Gut microbiota: an important player in type 2 diabetes mellitus. Frontiers in Cellular and Infection Microbiology, 2022;12:834485(1-15).
5. Sutcliffe EG, Mester JL, Susswein LR, Roberts ME, Marshall ML, Hruska KS. Fibroblast testing can inform medical management in individuals with mosaic variants detected on hereditary cancer panels. Cancer Genetics, 2022;266-267:86-89.
6. Purnamasari D, Tetrasiwi EN, Kartiko GJ, Astrella C, Husam K, Laksmi PW. Sarcopenia and chronic complications of type 2 diabetes mellitus. Review of Diabetic Studies, 2022;18(3):157-165.
7. Afsharmanesh MR, Mohammadi Z, Mansourian AR, Jafari SM. A review of micro RNAs changes in T2DM in animals and humans. Journal of Diabetes, 2023;15(8):649-664.
8. Zhang YY, Li YJ, Xue CD, Li S, Gao ZN, Qin KR. Effects of T2DM on cancer progression: pivotal precipitating factors and underlying mechanisms. Frontiers in Cellular and Infection Microbiology, 2024;15:1396022(1-16).
9. Wu X, Gao Y, Wang M, Peng H, Zhang D, Qin B, Pan L, Zhu G. Atherosclerosis indexes and incident T2DM in middle-aged and older adults: evidence from a cohort study. Diabetology & Metabolic Syndrome, 2023;15(1):23(1-9).
10. Fei Z, Xu Y, Zhang G, Liu Y, Li H, Chen L. Natural products with potential hypoglycemic activity in T2DM: 2019-2023. Phytochemistry, 2024;223:114130(1-21).
11. Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovascular Diabetology, 2022;21(1):74(1-15).
12. Lim LL, Chow E, Chan JCN. Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice. Nature Reviews Endocrinology, 2023;19(3):151-163.
13. Yang T, Liu Y, Li L, Zheng Y, Wang Y, Su J, Yang R, Luo M, Yu C. Correlation between the triglyceride-to-high-density lipoprotein cholesterol ratio and other unconventional lipid parameters with the risk of prediabetes and Type 2 diabetes in patients with coronary heart disease: a RCSCD-TCM study in China. Cardiovascular Diabetology, 2022;21(1):93(1-12).
14. Amad A, Naudet F, Fovet T. rTMS and depression: A correspondence you should take the time to read. Journal of Affective Disorders, 2023;330:214-215.
15. Bao Y, Han X, Liu D, Tan Z, Deng Y. Gut microbiota: The key to the treatment of metabolic syndrome in traditional Chinese medicine - a case study of diabetes and nonalcoholic fatty liver disease. Frontiers in Cellular and Infection Microbiology, 2022;13:1072376(1-17).
16. Yu C, Ruan Y, Sun X, Chen C, Shen T, Liu C, Qiu W, Lu Z, Chan SO, Wang L. rTMS ameliorates depression/anxiety-like behaviors in experimental autoimmune encephalitis by inhibiting neurotoxic reactive astrocytes. Journal of Affective Disorders, 2023;331:352-361.
17. Werida RH, Ramzy A, Ebrahim YN, Helmy MW. Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial. BMC Endocrine Disorders, 2023;23(1):259(1-10).
18. Liu C, Guo X. Adjuvant chinese medicine for the treatment of type 2 diabetes mellitus combined with mild cognitive impairment: a systematic review and meta-analysis of a randomised controlled trial. Pharmaceuticals (Basel), 2022;15(11):1424(1-14).
19. Xu W, Zhang Z, Lu Y, Li M, Li J, Tao W. Traditional Chinese medicine Tongxie Yaofang treating irritable bowel syndrome with diarrhea and type 2 diabetes mellitus in rats with liver-depression and spleen-deficiency: A preliminary study. Frontiers In Nutrition, 2022;9:968930(1-9).
20. Zhang S, Ma P, Chen Q. The correlation between the level of skin advanced glycation end products in type 2 diabetes mellitus and the stages of diabetic retinopathy and the types of traditional chinese medicine syndrome. Evidence-Based Complementary and Alternative Medicine, 2022;2022:5193944(1-8).
Copyright (c) 2025 Jiandi Zheng
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.